WeVote
Log In

Bill

Bill

HB 3834

Ibogaine clinical trials; Oklahoma Breakthrough Therapy Act; terms; requirements for drug developers; contractual terms; intellectual property rights; reports; intellectual property account; effective date.

2026 Regular Session Introduced by Avery Frix and 1 co-sponsor

Oklahoma authorizes ibogaine clinical trials under new "Breakthrough Therapy Act," establishing IP protections and state revenue-sharing to attract addiction research despite federal Schedule I restrictions.

Placed on General Order
0
WeVote Research Nonpartisan
Bill Summary · HB 3834

Legislative bill overview

HB 3834 establishes Oklahoma's "Breakthrough Therapy Act" to facilitate clinical trials for ibogaine, a psychoactive substance derived from an African shrub. The bill creates a regulatory framework allowing drug developers to conduct ibogaine research while defining intellectual property rights, licensing requirements, and financial arrangements through the state treasurer's office.

Why is this important

Ibogaine has shown potential in treating opioid addiction and other conditions in preliminary research, but remains a Schedule I controlled substance federally with limited U.S. clinical trial data. This legislation positions Oklahoma to potentially lead domestic research on a controversial drug and could influence national addiction treatment policy if trials prove successful. The bill also establishes financial incentives and IP protections to attract biotech investment to the state.

Potential points of contention

  • Federal-state conflict: Ibogaine's Schedule I status creates legal tension; researchers may face federal prosecution despite state authorization
  • Safety and efficacy concerns: Limited clinical data on ibogaine's safety profile; adverse effects and contraindications remain poorly documented compared to established addiction treatments
  • IP and financial arrangements: The bill's structure for state revenue-sharing and intellectual property ownership may raise questions about appropriate use of public resources and whether the state bears disproportionate risk versus developers

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.